alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1005 Acetic acid. ( a ) Acetic acid (C2H4O2, CAS Reg. No. 64-19-7) is known as ethanoic acid. It occurs naturally in plant and animal tissues. It is produced by fermentation of carbohydrates or by organic synthesis. The principal synthetic methods currently employed are oxidation of acetaldehyde derived from ethylene, liquid phase oxidation of butane, and reaction of carbon monoxide with methanol derived from natural gas.
( b ) The ingredient meets the specifications of the Food Chemicals Codex, 3d Ed. (1981), p. 8, which is incorporated by reference. Copies are available from the National Academy Press, 2101 Constitution Ave. NW., Washington, DC 20418, or available for inspection at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) The ingredient is used as a curing and pickling agent as defined in § 170.3(o)(5) of this chapter; flavor enhancer as defined in § 170.3(o)(11) of this chapter; flavoring agent and adjuvant as defined in § 170.3(o)(12) of this chapter; pH control agent as defined in § 170.3(o)(23) of this chapter; as a solvent and vehicle as defined in § 170.3(o)(27) of this chapter; and as a boiler water additive complying with § 173.310 of this chapter.
( d ) The ingredient is used in food at levels not to exceed current good manufacturing practice in accordance with § 184.1(b)(1). Current good manufacturing practice results in a maximum level as served, of 0.25 percent for baked goods as defined in § 170.3(n)(1) of this chapter; 0.8 percent for cheeses as defined in § 170.3(n)(5) of this chapter and dairy product analogs as defined in § 170.3(n)(10) of this chapter; 0.5 percent for chewing gum as defined in § 170.3(n)(6) of this chapter; 9.0 percent for condiments and relishes as defined in § 170.3(n)(8) of this chapter; 0.5 percent for fats and oils as defined in § 170.3(n)(12) of this chapter; 3.0 percent for gravies and sauces as defined in § 170.3(n)(24) of this chapter; 0.6 percent for meat products as defined in § 170.3(n)(29) of this chapter; and 0.15 percent or less for all other food categories. The ingredient may also be used in boiler water additives at levels not to exceed current good manufacturing practice.
( e ) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.
[47 FR 27814, June 25, 1982]
§ 211.166 Stability testing. ( a ) There shall be a written testing program designed to assess the stability characteristics of drug products. The results of such stability testing shall be used in determining appropriate storage conditions and expiration dates. The written program shall be followed and shall include: ( 1 ) Sample size and test intervals based on statistical criteria for each attribute examined to assure valid estimates of stability;
( 2 ) Storage conditions for samples retained for testing;
( 3 ) Reliable, meaningful, and specific test methods;
( 4 ) Testing of the drug product in the same container-closure system as that in which the drug product is marketed;
( 5 ) Testing of drug products for reconstitution at the time of dispensing (as directed in the labeling) as well as after they are reconstituted.
( b ) An adequate number of batches of each drug product shall be tested to determine an appropriate expiration date and a record of such data shall be maintained. Accelerated studies, combined with basic stability information on the components, drug products, and container-closure system, may be used to support tentative expiration dates provided full shelf life studies are not available and are being conducted. Where data from accelerated studies are used to project a tentative expiration date that is beyond a date supported by actual shelf life studies, there must be stability studies conducted, including drug product testing at appropriate intervals, until the tentative expiration date is verified or the appropriate expiration date determined.
( c ) For homeopathic drug products, the requirements of this section are as follows: ( 1 ) There shall be a written assessment of stability based at least on testing or examination of the drug product for compatibility of the ingredients, and based on marketing experience with the drug product to indicate that there is no degradation of the product for the normal or expected period of use.
( 2 ) Evaluation of stability shall be based on the same container-closure system in which the drug product is being marketed.
( d ) Allergenic extracts that are labeled “No U.S. Standard of Potency” are exempt from the requirements of this section.
[43 FR 45077, Sept. 29, 1978, as amended at 46 FR 56412, Nov. 17, 1981]
# L_2019250EN.01008001.xml

| 30.9.2019 | EN | Official Journal of the European Union | L 250/80 |
| --- | --- | --- | --- |

30.9.2019

EN

Official Journal of the European Union

L 250/80

---

COUNCIL DECISION (EU) 2019/1609

of 24 September 2019

appointing a member, proposed by the Hellenic Republic, of the Committee of the Regions

THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty on the Functioning of the European Union, and in particular Article 305 thereof,

Having regard to the proposal of the Greek Government,

Whereas:

| (1) | On 26 January 2015, 5 February 2015 and 23 June 2015, the Council adopted Decisions (EU) 2015/116 (1), (EU) 2015/190 (2) and (EU) 2015/994 (3) appointing the members and alternate members of the Committee of the Regions for the period from 26 January 2015 to 25 January 2020. |
| --- | --- |

(1)

On 26 January 2015, 5 February 2015 and 23 June 2015, the Council adopted Decisions (EU) 2015/116 (1), (EU) 2015/190 (2) and (EU) 2015/994 (3) appointing the members and alternate members of the Committee of the Regions for the period from 26 January 2015 to 25 January 2020.

| (2) | A member's seat has become vacant following the end of the term of office of Mr Georgios KAMINIS, |
| --- | --- |

(2)

A member's seat has become vacant following the end of the term of office of Mr Georgios KAMINIS,

HAS ADOPTED THIS DECISION:

Article 1

The following is hereby appointed as a member of the Committee of the Regions for the remainder of the current term of office, which runs until 25 January 2020:

| — | Mr Dimitrios BIRMPAS, Electorate Mandate Municipality of Egaleo. |
| --- | --- |

—

Mr Dimitrios BIRMPAS, Electorate Mandate Municipality of Egaleo.

Article 2

This Decision shall enter into force on the date of its adoption.

Done at Brussels, 24 September 2019.

For the Council

The President

K. KULMUNI

---

(1)  Council Decision (EU) 2015/116 of 26 January 2015 appointing the members and alternate members of the Committee of the Regions for the period from 26 January 2015 to 25 January 2020 (OJ L 20, 27.1.2015, p. 42).

1

(2)  Council Decision (EU) 2015/190 of 5 February 2015 appointing the members and alternate members of the Committee of the Regions for the period from 26 January 2015 to 25 January 2020 (OJ L 31, 7.2.2015, p. 25).

2

(3)  Council Decision (EU) 2015/994 of 23 June 2015 appointing the members and alternate members of the Committee of the Regions for the period from 26 January 2015 to 25 January 2020 (OJ L 159, 25.6.2015, p. 70).

3

---
§ 182.6085 Sodium acid phosphate. ( a ) *Product.* Sodium acid phosphate.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing practice.
§ 21.45 Fees. ( a ) Where applicable, fees for copying records shall be charged in accordance with the schedule set forth in this section. Fees may only be charged where an individual has requested that a copy be made of a record to which he is granted access. No fee may be charged for making a search of a Privacy Act Record System whether the search is manual, mechanical, or electronic. Where a copy of the record must be made to provide access to the record, e.g., computer printout where no screen reading is available, the copy shall be made available to the individual without cost. Where a medical record is made available to a representative designated by the individual under § 21.33, no fee will be charged.
( b ) The fee schedule is as follows: ( 1 ) Copying of records susceptible to photocopying—$.10 per page.
( 2 ) Copying of records not susceptible to photocopying, e.g., punch cards or magnetic tapes—at actual cost to the determined on a case-by-case basis.
( 3 ) No charge will be made if the total amount of copying for an individual does not exceed $25.
( c ) When a fee is to be assessed, the individual shall be notified prior to the processing of the copies, and be given an opportunity to amend his request. Payment shall be made by check or money order made payable to the “Food and Drug Administration,” and shall be sent to the Accounting Branch (HFA-120), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857. Advance deposit shall be required where the total amount exceeds $50.
[42 FR 15626, Mar. 22, 1977, as amended at 54 FR 9038, Mar. 3, 1989]
### Docket No: FAA

- 2015

- 3636 Dir ID: 2015

- NM

- 043

- AD

. C on t acts. W ith w h o m o u tside t he F A A h a s th i s prop os al been di s cu s sed?

Organ i zat i on P erson C ont a cted D ate R e s pon s e

N at i o n a l B u s ine s s Air c r af t As s o ci at i o n E li C ott i 3 / 10 / 1 5

Re g i o n a l Airline A ss o ci at i o n 3 / 10 / 1 5

Air c r af t O w ners & P il o t s A s s o ci at i o n R o bert Ha ck m a n 3 / 10 / 1 5

Airlines fo r A m e r ica R o bert I r e l a nd 3 / 10 / 1 5
Office for Domestic Preparedness 

U.S. Department of Homeland Security 

Washington, DC 20531

ODP Information Bulletin

No. 140 November 16, 2004

 

TO All State Administrative Agency Heads

 All State Administrative Agency Points of Contact

 All State Homeland Security Directors

 All Urban Area Core City/Core County Points of Contact

 

FROM: C. Suzanne Mencer

 Executive Director

 

SUBJECT: Advanced Commercial Vehicle Criminal and Terrorist Interdiction Training

 Based on numerous requests, the Office for Domestic Preparedness has reviewed and is hereby 

announcing its approval of curriculum submitted through the Florida State Administrative 

Agency. The following course is now approved for use of ODP grant funds based on the 

conditions enumerated below.

PERFORMANCE LEVEL: Advanced Commercial Vehicle Criminal and Terrorist 

Interdiction Training 

The course provides training for sworn police officers and sworn transportation inspectors who 

execute inspections and enforcement actions relating to over the road commercial traffic. The goal 

of this course is to help law enforcement detect/deter/interrupt the potential delivery of weapons of 

mass destruction via over the road vehicles.

 The delivery of this course must be consistent with the implementation of the approved State or 

Urban Area Homeland Security Plan and the priorities enumerated therein. The course may be 

delivered provided the following conditions are met:

• Since the course deals with issues of investigation, arrest, search and seizure, its use with 

respect to DHS funding should be limited to sworn officers in venues whose core functions 

focus on commercial enforcement. 

• Considering the high risk that may accompany compartment searches containing weapons of 

mass destruction, the State or Urban Area must cite and verify the following prerequisites 

during the student selection process 

o completion of awareness level training in incident command

AND

o completion of awareness level training in WMD or hazardous materials 

training. This hazardous materials certification shall comply with 29 CFR 1910 to 

promote officer safety.

Further requests for information should be directed to the Centralized Scheduling and Information Desk at 

1-800-368-6498.
<TABLE> <S> <C>

<ARTICLE> 9
<CIK> 0000945532
<NAME> USABANCSHARES, INC.
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-END>                               DEC-31-1997
<CASH>                                         833,176
<INT-BEARING-DEPOSITS>                       3,975,261
<FED-FUNDS-SOLD>                                     0
<TRADING-ASSETS>                                     0
<INVESTMENTS-HELD-FOR-SALE>                  9,034,725
<INVESTMENTS-CARRYING>                      15,418,904
<INVESTMENTS-MARKET>                        15,643,630
<LOANS>                                     56,570,104
<ALLOWANCE>                                    567,940
<TOTAL-ASSETS>                              89,325,976
<DEPOSITS>                                  70,473,521
<SHORT-TERM>                                12,637,942
<LIABILITIES-OTHER>                            848,730
<LONG-TERM>                                          0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       813,807
<OTHER-SE>                                   4,551,976
<TOTAL-LIABILITIES-AND-EQUITY>              89,325,976
<INTEREST-LOAN>                              3,089,857
<INTEREST-INVEST>                            1,637,461
<INTEREST-OTHER>                               151,727
<INTEREST-TOTAL>                             4,879,045
<INTEREST-DEPOSIT>                           2,284,951
<INTEREST-EXPENSE>                             245,299
<INTEREST-INCOME-NET>                        2,348,795
<LOAN-LOSSES>                                  415,000
<SECURITIES-GAINS>                             127,458
<EXPENSE-OTHER>                              2,456,970
<INCOME-PRETAX>                              (208,717)
<INCOME-PRE-EXTRAORDINARY>                   (208,717)
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (225,608)
<EPS-PRIMARY>                                   (0.28)
<EPS-DILUTED>                                   (0.28)
<YIELD-ACTUAL>                                    9.41
<LOANS-NON>                                    286,897
<LOANS-PAST>                                   165,418
<LOANS-TROUBLED>                                     0
<LOANS-PROBLEM>                                      0
<ALLOWANCE-OPEN>                               182,079
<CHARGE-OFFS>                                  (29,139)
<RECOVERIES>                                         0
<ALLOWANCE-CLOSE>                              567,940
<ALLOWANCE-DOMESTIC>                                 0
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                        567,940

</TABLE>
<PAGE>   1

                                                                    EXHIBIT 99.5


                                RULE 438 CONSENT


        In accordance with Rule 438 under the Securities Act of 1933, as
amended, the undersigned hereby consents to being named as a prospective
director of United Security Bancorporation ("USBN") in the Registration
Statement on Form S-4 that has been prepared by counsel and will be filed by
USBN with the Securities and Exchange Commission.


                                       /s/ Wes Colley
                                       -----------------------------------------
                                       Wes Colley

                                       Dated Signed:  12/11/98
                                                    ----------------------------
Exhibit 32.1
 
 Certification Pursuant to 18 U.S.C. Section 1350,
 As Adopted Pursuant to Section 906 of the
 Sarbanes - Oxley Act of 2002
 
 In connection with the Quarterly Report of Semele Group, Inc. and subsidiaries (Semele or the Company), on Form 10-QSB for the period ended June 30, 2004 as filed with the Securities and Exchange Commission on the date hereof (the Report), the undersigned, the Principal Executive Officer of the Trusts Managing Trustee, hereby certifies pursuant to 18 U.S.C. §1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 that:
 
 (1)  the Report of the Trust filed today fully complies with the requirements of Section 13(a) or 15 (d) of the Securities Exchange Act of 1934; and
 
 (2)  the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Trust.
 
 /s/ Gary D. Engle
 Gary D. Engle
 President of AFG ASIT Corporation,
 the Managing Trustee of the Trust
 (Principal Executive Officer)
 August, 23, 2004
<TABLE> <S> <C>


<ARTICLE>                        5
<LEGEND>
This schedule contains summary financial information extracted from Kideo
Productions, Inc. and is qualified in its entirety by reference to such
financial statements.
</LEGEND>
<MULTIPLIER>                     1,000
       
<S>                              <C>
<PERIOD-TYPE>                    YEAR
<FISCAL-YEAR-END>                               JUL-31-1998
<PERIOD-START>                                  AUG-01-1997
<PERIOD-END>                                    JUL-31-1998
<CASH>                                                   82
<SECURITIES>                                              0
<RECEIVABLES>                                            92
<ALLOWANCES>                                              0
<INVENTORY>                                              53
<CURRENT-ASSETS>                                        396
<PP&E>                                                  925
<DEPRECIATION>                                          705
<TOTAL-ASSETS>                                        1,071
<CURRENT-LIABILITIES>                                 2,409
<BONDS>                                                  10
<PREFERRED-MANDATORY>                                     0
<PREFERRED>                                               0
<COMMON>                                                  0
<OTHER-SE>                                           (1,348)
<TOTAL-LIABILITY-AND-EQUITY>                          1,071
<SALES>                                               2,033
<TOTAL-REVENUES>                                      2,033
<CGS>                                                 1,639
<TOTAL-COSTS>                                         2,761
<OTHER-EXPENSES>                                          0
<LOSS-PROVISION>                                          0
<INTEREST-EXPENSE>                                      363
<INCOME-PRETAX>                                      (2,730)
<INCOME-TAX>                                              0
<INCOME-CONTINUING>                                  (2,730)
<DISCONTINUED>                                            0
<EXTRAORDINARY>                                           0
<CHANGES>                                                 0
<NET-INCOME>                                         (2,730)
<EPS-PRIMARY>                                          (.76)
<EPS-DILUTED>                                          (.76)
        


</TABLE>
§ 200.5 Mailing of important information about drugs. Manufacturers and distributors of drugs and the Food and Drug Administration occasionally are required to mail important information about drugs to physicians and others responsible for patient care. In the public interest, such mail should be distinctive in appearance so that it will be promptly recognized and read. The Food and Drug Administration will make such mailings in accordance with the specifications set forth in this section. Manufacturers and distributors of drugs are asked to make such mailings as prescribed by this section and not to use the distinctive envelopes for ordinary mail. ( a ) Use first class mail and No. 10 white envelopes.
( b ) The name and address of the agency or the drug manufacturer or distributor is to appear in the upper left corner of the envelope.
( c ) The following statements are to appear in the far left third of the envelope front, in the type and size indicated, centered in a rectangular space approximately 3 inches wide and 21 ⁄ 4 inches high with an approximately 3 ⁄ 8 inch-wide border in the color indicated: ( 1 ) When the information concerns a significant hazard to health, the statement: IMPORTANT DRUG WARNING
The statement shall be in three lines, all capitals, and centered. “Important” shall be in 36 point Gothic Bold type. “Drug” and “Warning” shall be in 36 point Gothic Condensed type. The rectangle's border and the statement therein shall be red.
( 2 ) When the information concerns important changes in drug package labeling, the statement: IMPORTANT PRESCRIBING INFORMATION
The statement shall be in three lines, all capitals, and centered. “Important” shall be in 36 point Gothic Bold type. “Prescribing” and “Information” shall be in 36 point Gothic Condensed type. The rectangle's border and the statement therein shall be blue.
( 3 ) When the information concerns a correction of prescription drug advertising or labeling, the statement: IMPORTANT CORRECTION OF DRUG INFORMATION
The statement shall be in four lines, all capitals, and centered. “Important” shall be in 36 point Gothic Bold type. “Correction,” “Of Drug,” and “Information” shall be in 36 point Gothic Condensed type. The rectangle's border and the statement therein shall be brown.
Exhibit 15.3
  [BDO Auditores S.L. letterhead]


CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
  We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (File Nos. 333-187533, 333-102288 and 333-92491)  pertaining to the Employee Stock Option plans of Ellomay Capital Ltd. (the “Company”) and Form F-3 (File Nos. 333-199696 and 333-144171) of the Company of our report dated April 29, 2015 with respect to the financial statements of Rodríguez I Parque Solar, S.L. included in the Annual Report on Form 20-F of the Company for the year ended December 31, 2014.
  /s/ BDO Auditores S.L.
  BDO Auditores S.L.
  Certified Public Accountants
  Madrid, Spain
 April 29, 2015